![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Catco Reinsurance Opportunities Fund Limited | LSE:CAT | London | Ordinary Share | BMG1961Q3242 | ORD USD0.00013716 (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.00 | 13.00 | 35.00 | 24.00 | 24.00 | 24.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Unit Inv Tr, Closed-end Mgmt | 6.33M | 5.44M | 3.6440 | 6.59 | 35.84M |
RNS Number:9322Q Cambridge Antibody Tech Group PLC 14 September 2000 00/CAT/12 Page 1 of 3 For Further Information Contact: Cambridge Antibody Technology Tel: +44 (0) 1763 263233 Dr David Glover, Medical Director John Aston, Finance Director Rowena Gardner, Communications Manager HCC De Facto (Europe) Tel: +44 (0) 20 7496 3300 Nikul Odedra (trade) Sue Charles (city/financial) BMC Communications/The Trout Group (USA) Tel: 001 212 477 9007 Brad Miles, ext 17 (media) Jonathan Fassberg, ext.16 (investors) CAT ENTERS INTO PRODUCT DEVELOPMENT AGREEMENT WITH WYETH RESEARCH RELATING TO ALZHEIMER'S AMYLOID BETA TARGET Melbourn, UK... Cambridge Antibody Technology - (LSE:CAT) ("CAT") announced today that it has granted Wyeth-Ayerst Research (the pharmaceutical research unit of American Home Products Corporation - (NYSE:AHP) an exclusive product licence to develop antibody drug products specific for the amyloid ( peptide that has been widely implicated in Alzheimer's disease. This development reflects the success of the broad collaboration between CAT and Wyeth-Ayerst, signed in March 1999, to apply CAT's functional genomics and antibody engineering expertise to the discovery of new therapeutics based on targets identified by Wyeth-Ayerst. Under terms of the product development agreement, CAT will receive an advance licensing fee, and will potentially receive clinical milestones and royalties associated with product sales. Page 2 of 3 Wyeth-Ayerst recently announced an alliance with Elan Corporation, plc to develop immuno-therapeutic agents that may be used for the treatment of mild to moderate Alzheimer's disease and possibly prevent the onset of the disease. The agreement between CAT and Wyeth-Ayerst allows Wyeth-Ayerst and Elan to use CAT's technology to further explore both preventative and therapeutic treatments for the disease. "We are enthusiastic to be moving our collaboration with Wyeth-Ayerst forward at this important and exciting time of discovery in the field of Alzheimer's disease," says David Chiswell, CEO of CAT. "We believe amyloid ( to have strong potential as a therapeutic antibody target, as Wyeth-Ayerst's and Elan's target validation work in this area has demonstrated. We are also confident our ongoing alliance with Wyeth will continue to help fuel our antibody product pipeline." Notes to Editors: Cambridge Antibody Technology (CAT) * CAT is a UK biotechnology company using its proprietary technologies in fully human monoclonal antibodies for drug discovery and drug development. Based in Melbourn, 10 miles south of Cambridge, England, CAT currently employs around 180 people. * CAT is listed on the London Stock Exchange, having raised #41m in its IPO in March 1997. An Open Offer and International Offering in March 2000 raised #93m. * CAT has a world-leading platform technology for rapidly isolating fully human monoclonal antibodies using phage display systems. CAT has an extensive phage display antibody library, currently incorporating around 100 billion distinct antibodies. This library forms the basis for the company's strategy to develop a portfolio of clinical development programmes and for discovering new drug leads using functional genomics. Four fully human therapeutic antibodies developed by CAT are at various stages of clinical trials. * CAT has a number of license and collaborative agreements in place with pharmaceutical and biotechnology companies including: Eli Lilly, Pfizer, BASF Pharma, Genentech, ICOS Corporation, Genetics Institute, Wyeth-Ayerst, Human Genome Sciences, AstraZeneca and Pharmacia. Wyeth-Ayerst (American Home Products Corporation: NYSE: AHP) Wyeth-Ayerst Laboratories, a division of American Home Products Corporation (NYSE:AHP), is a major research-oriented pharmaceutical company with leading products in the areas of women's health care, cardiovascular therapies, central nervous system drugs, anti-inflammatory agents, infectious disease, haemophilia, oncology, vaccines, and generic pharmaceuticals. American Home Products Corporation (NYSE:AHP) is one of the worlds largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs and over-the-counter medications. It is also a leader in vaccines, biotechnology, and animal health care. Page 3 of 3 Elan Corporation plc (NYSE: ELN) Elan is a leading worldwide speciality pharmaceutical and drug delivery company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel. Elan is focused on the discovery, development and marketing of therapeutic products and services in neurology, pain management and oncology, and on the development and commercialisation of products using its extensive range of proprietary drug delivery technologies. Elan's shares trade on the New York, London and Dublin Stock Exchanges. Alzheimer's Disease * Alzheimer's disease is a progressive, degenerative disease of the brain, primarily afflicting older persons. Initial symptoms include simple confusion and forgetfulness; ultimately leading to profound dementia. * Alzheimer's disease affects one person in 10 over the age of 65, and almost half of all persons over 85. These are the two most rapidly growing population segments in Western Europe, the USA and Japan. * Approximately 15-million people worldwide suffer from Alzheimer's disease. Amyloid * Amyloid ( plaques have been observed in the brains of people who died with Alzheimer's disease and it is believed that it is the presence of these plaques that leads to degeneration of cognitive function in Alzheimer's patients).
1 Year Catco Reinsurance Opport... Chart |
1 Month Catco Reinsurance Opport... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions